一个意大利多学科的德尔菲共识关于关于Pidotimod的临床相关性的新见解
Gianluigi Marseglia1, Matteo Gelardi2, Paola Marchisio3
1Università di Pavia.
Multidisciplinary respiratory medicine
|December 1, 2025
概括
合成二胺的皮多蒂莫德是预防和治疗儿童和成人复发性呼吸道感染的有效和安全药物. 专家们就其在包括肺炎和COVID-19在内的各种疾病中使用达成共识.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 皮多蒂莫德是一种合成二,具有已证明的免疫调节作用.
- 广泛的科学文献支持pidotimod在各种临床场景中的有效性和安全性.
- 一个多学科的德尔菲共识旨在增强临床医生的理解和应用pidotimod.
研究的目的:
- 巩固专家对皮多蒂莫德临床应用的意见.
- 为了提供基于证据的指导,为pidotimod的知情使用提供指导.
- 评估关于皮多蒂莫德在治疗感染和免疫相关疾病中的作用的共识.
主要方法:
- 一个涉及意大利专家 (儿科医生,耳鼻喉科医生,过敏学家,肺病学家) 的多学科德尔菲共识.
- 通过网络平台对有关使用pidotimod的陈述进行匿名投票.
- 基于有效性和安全性的科学证据建立共识.
主要成果:
- 专家们完全同意科学证据支持皮多蒂莫德的疗效和安全性.
- 关于皮多蒂莫德在预防和治疗复发性呼吸道感染 (儿童和成人) 的功效的协议.
- 关于皮多蒂莫德在肺炎,唐氏综合征,COVID-19,PFAPA,喘息和尿路感染中的辅助使用的共识.
结论:
- 皮多蒂莫德是一种安全有效的免疫调节剂.
- 它有助于预防易感个体的复发性呼吸道感染.
- 皮多蒂莫德作为一种有价值的辅助疗法,用于管理各种感染.
相关概念视频
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
507
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
507
01:29Chronic Pancreatitis II: Collaborative Care
291
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
291
01:21Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
326
Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
326
01:17Drugs for Treatment of Diarrhea-Predominant IBS
599
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
599
01:11Clinical Trials: Overview
4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
461
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
461